

CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WI000327 AGE/SEX :35 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID :TRUPF010519880

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

DELHI ABHA NO

RECEIVED: 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28 **NEW DELHI 110030** 8800465156

Biological Reference Interval Test Report Status Results Units **Final**

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

ECG

WITHIN NORMAL LIMITS **ECG**

MEDICAL HISTORY

RELEVANT PRESENT HISTORY NOT SIGNIFICANT RELEVANT PAST HISTORY NOT SIGNIFICANT

MARRIED / VEG DIET / NO ALLERGIES / NO SMOKING / NO ALCOHOL. RELEVANT PERSONAL HISTORY

REGULAR 32-35/3 MENSTRUAL HISTORY (FOR FEMALES)

LMP (FOR FEMALES) 8/9/2023 OBSTETRIC HISTORY (FOR FEMALES) 2 FTND A0 L2

RELEVANT FAMILY HISTORY THYROID DISEASE :- MOTHER

HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.64 mts WEIGHT IN KGS. Kgs 60

BMI 22 BMI & Weight Status as follows/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

DRAWN

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL **NORMAL** PHYSICAL ATTITUDE GENERAL APPEARANCE / NUTRITIONAL **HEALTHY**

STATUS

BUILT / SKELETAL FRAMEWORK AVERAGE FACIAL APPEARANCE **NORMAL NORMAL** SKIN **NORMAL** UPPER LIMB **NORMAL** LOWER LIMB **NECK** NORMAL

NOT ENLARGED OR TENDER NECK LYMPHATICS / SALIVARY GLANDS

Page 1 Of 21





Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956





CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WI000327 AGE/SEX :35 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID :TRUPF010519880

DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 09/09/2023 09:50:15 DELHI

ABHA NO REPORTED :11/09/2023 15:17:28 **NEW DELHI 110030** 8800465156

Biological Reference Interval Test Report Status Results Units <u>Final</u>

NOT ENLARGED THYROID GLAND

NORMAL CAROTID PULSATION TEMPERATURE **NORMAL**

84/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID **PULSE**

BRUIT

RESPIRATORY RATE **NORMAL**

CARDIOVASCULAR SYSTEM

BP 110/74 MM HG mm/Hg

(SUPINE)

PERICARDIUM NORMAL APEX BEAT **NORMAL HEART SOUNDS NORMAL MURMURS ABSENT**

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST **NORMAL** MOVEMENTS OF CHEST **SYMMETRICAL BREATH SOUNDS INTENSITY NORMAL**

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ABSENT ADDED SOUNDS

PER ABDOMEN

NORMAL **APPEARANCE VENOUS PROMINENCE** ABSENT

NOT PALPABLE **LIVER** NOT PALPABLE **SPLEEN**

ABSENT **HERNIA**

CENTRAL NERVOUS SYSTEM

NORMAL HIGHER FUNCTIONS CRANIAL NERVES **NORMAL** CEREBELLAR FUNCTIONS **NORMAL** SENSORY SYSTEM **NORMAL** MOTOR SYSTEM **NORMAL** NORMAL REFLEXES

MUSCULOSKELETAL SYSTEM

Page 2 Of 21









CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WI000327 AGE/SEX :35 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : TRUPF010519880 DRAWN

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 09/09/2023 09:50:15 DELHI ABHA NO REPORTED :11/09/2023 15:17:28 **NEW DELHI 110030**

Biological Reference Interval Test Report Status Results Units <u>Final</u>

NORMAL SPINE

NORMAL JOINTS

BASIC EYE EXAMINATION

CONJUNCTIVA **NORMAL EYELIDS** NORMAL EYE MOVEMENTS **NORMAL** CORNEA **NORMAL**

DISTANT VISION RIGHT EYE WITHOUT WITHIN NORMAL LIMIT

GLASSES

8800465156

WITHIN NORMAL LIMIT DISTANT VISION LEFT EYE WITHOUT

GLASSES

WITHIN NORMAL LIMIT NEAR VISION RIGHT EYE WITHOUT GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT **NORMAL** COLOUR VISION

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT **NOT SIGNIFICANT** RELEVANT GP EXAMINATION FINDINGS

DRINK 2-3 LITRE WATER DAILY. REMARKS / RECOMMENDATIONS

REPEAT URINE ROUTINE AFTER 1 MONTH. SURJICAL CONSULT FOR UMBILICAL HERNIA.

Page 3 Of 21









 CODE/NAME & ADDRESS : C000138394
 ACCESSION NO : 0181WI000327
 AGE/SEX : 35 Years
 Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 | |PATIENT ID : TRUPF010519880

PATIENT ID : [RUPF010519880

CLIENT PATIENT ID: ABHA NO : DDAWN .

RECEIVED : 09/09/2023 09:50:15

REPORTED :11/09/2023 15:17:28

Test Report Status <u>Final</u> Results Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

UMBILICAL HERNIA.

NO OTHER SIGNIFICANT ABNORMILITY IS SEEN.

TMT OR ECHO

TMT OR ECHO

2D ECHO:- NORMAL

Interpretation(s)

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Page 4 Of 21





view Details

View Repor

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956







CODE/NAME & ADDRESS: C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

ACCESSION NO: 0181WI000327

PATIENT ID : TRUPF010519880

CLIENT PATIENT ID: ABHA NO

AGE/SEX

:35 Years Female

DRAWN

RECEIVED: 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28

Biological Reference Interval Test Report Status Results Units <u>Final</u>

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE			
BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB) METHOD: SLS- HEMOGLOBIN DETECTION METHOD	12.8	12.0 - 15.0	g/dL	
RED BLOOD CELL (RBC) COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION	4.55	3.8 - 4.8	mil/μL	
WHITE BLOOD CELL (WBC) COUNT METHOD: FLUORESCENCE FLOW CYTOMETRY	8.52	4.0 - 10.0	thou/μL	
PLATELET COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION	561 High	150 - 410	thou/μL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV) METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD	40.9	36.0 - 46.0	%	
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED FROM RBC & HCT	89.9	83.0 - 101.0	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED FROM THE RBC & HGB	28.1	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED FROM THE HGB & HCT	31.3 Low	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE	13.2	11.6 - 14.0	%	
MENTZER INDEX	19.8			
MEAN PLATELET VOLUME (MPV)	9.1	6.8 - 10.9	fL	
METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMA	ATOCRIT			
WBC DIFFERENTIAL COUNT				
NEUTROPHILS METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	63	40 - 80	%	
LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	24	20 - 40	%	
MONOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	7	2 - 10	%	
EOSINOPHILS METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	6	1 - 6	%	

Bhinchkhede,

Dr. Priyal Chinchkhede, MD **Consultant Pathologist**





Page 5 Of 21



Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India

Fax: CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS: C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181WI000327

PATIENT ID :TRUPF010519880

CLIENT PATIENT ID:

ABHA NO

AGE/SEX :35 Years Female

RECEIVED: 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28

	ļ		
Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
BASOPHILS	0	0 - 1	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE NEUTROPHIL COUNT	5.37	2.0 - 7.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE LYMPHOCYTE COUNT	2.04	1.0 - 3.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE MONOCYTE COUNT	0.55	0.2 - 1.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE EOSINOPHIL COUNT	0.51 High	0.02 - 0.50	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.6		
MORPHOLOGY			
RBC	NORMOCYTIC NORM	1OCHROMIC	
WBC	NORMAL MORPHOLO	OGY	
METHOD: MICROSCOPIC EXAMINATION			
PLATELETS	INCREASED		

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

This ratio element is a calculated parameter and out of NABL scope.

Bhinchkhede.

Dr. Priyal Chinchkhede, MD **Consultant Pathologist**





Page 6 Of 21



Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







REF. DOCTOR: SELF PATIENT NAME: TRUPTI CHOPADE

CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181WI000327 AGE/SEX :35 Years Female

PATIENT ID :TRUPF010519880 DRAWN

CLIENT PATIENT ID: RECEIVED: 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28 ABHA NO

Test Report Status Biological Reference Interval Final Results Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

0 - 20mm E.S.R

METHOD: MODIFIED WESTERGREN

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

HBA1C 5.2 Non-diabetic Adult < 5.7 %

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0

Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 102.5 < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sédimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are réported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.

Page 7 Of 21







Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WI000327 AGE/SEX :35 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : TRUPF010519880

DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED: 09/09/2023 09:50:15 DELHI ABHA NO REPORTED :11/09/2023 15:17:28 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** <u>Final</u> Units

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Page 8 Of 21







Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







CODE/NAME & ADDRESS: C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

8800465156

NEW DELHI 110030

ACCESSION NO: 0181WI000327

PATIENT ID :TRUPF010519880

CLIENT PATIENT ID: ABHA NO

AGE/SEX :35 Years Female

DRAWN

RECEIVED: 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD: GEL COLUMN AGGLUTINATION METHOD.

RH TYPE **POSITIVE**

METHOD: GEL COLUMN AGGLUTINATION METHOD.

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

@hindrehede

Dr.Priyal Chinchkhede, MD **Consultant Pathologist**





Page 9 Of 21



Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







PATIENT NAME: TRUPTI CHOPADE

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

REF. DOCTOR: SELF

:TRUPF010519880

ACCESSION NO: 0181WI000327 AGE/SEX :35 Years Female

DRAWN

RECEIVED: 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28

ABHA NO

CLIENT PATIENT ID:

PATIENT ID

Test Report Status <u>Final</u> Results

Biological Reference Interval Units

BIOCHEMISTRY

78

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA


FBS (FASTING BLOOD SUGAR)

Normal 75 - 99

mg/dL

Pre-diabetics: 100 - 125 Diabetic: > or = 126

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE



GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE

84

70 - 139

mg/dL



Dr.Priyal Chinchkhede, MD **Consultant Pathologist**

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 10 Of 21

Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







PATIENT NAME: TRUPTI CHOPADE

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

REF. DOCTOR: SELF

ACCESSION NO: 0181WI000327 PATIENT ID : TRUPF010519880


CLIENT PATIENT ID: ABHA NO

AGE/SEX :35 Years Female

DRAWN

RECEIVED: 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>



LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL 118 Desirable: < 200 mg/dL

Borderline: 200 - 239 High: > / = 240

METHOD: ENZYMATIC COLORIMETRIC ASSAY

TRIGLYCERIDES 95 Normal: < 150 mg/dL

Borderline high: 150 - 199

High: 200 - 499 Very High: >/= 500

METHOD: ENZYMATIC COLORIMETRIC ASSAY

METHOD: ENZYMATIC, COLORIMETRIC

HDL CHOLESTEROL 48 At Risk: < 40 mg/dL

Desirable: > or = 60

CHOLESTEROL LDL 51 Adult levels:

Optimal < 100

Near optimal/above optimal:

100-129

Borderline high: 130-159

High: 160-189 Very high: = 190

METHOD: ENZYMATIC COLORIMETRIC ASSAY



Dr. Priyal Chinchkhede, MD **Consultant Pathologist**

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head

mg/dL



Page 11 Of 21





Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:



8800465156





PATIENT NAME: TRUPTI CHOPADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394 ACCESSION NO : **0181WI000327** AGE/SEX : 35 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : TRUPF010519880 DRAWN

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED : 09/09/2023 09:50:15

NEW DELHI 110030 REPORTED :11/09/2023 15:17:28

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
NON HDL CHOLESTEROL	70	Desirable : < 130 mg/dL Above Desirable : $130 - 159$ Borderline High : $160 - 189$ High : $190 - 219$ Very high : $> / = 220$
VERY LOW DENSITY LIPOPROTEIN	19.0	< OR = 30.0 mg/dL
CHOL/HDL RATIO	2.5 Low	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0
LDL/HDL RATIO	1.1	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category				
Extreme risk group	A.CAD with > 1 feature of high risk group			
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =		
	50 mg/dl or polyvascular disease			
Very High Risk	1. Established ASCVD 2. Diabetes with 2 1	najor risk factors or evidence of end organ damage 3.		
	Familial Homozygous Hypercholesterolemi	a		
High Risk	1. Three major ASCVD risk factors. 2. Dia	betes with 1 major risk factor or no evidence of end organ		
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary			
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque			
Moderate Risk	2 major ASCVD risk factors			
Low Risk	0-1 major ASCVD risk factors			
Major ASCVD (Ath	Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use				
2. Family history of premature ASCVD 4. High blood pressure				
5. Low HDL				
		•		

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

ter er treatment goals and statin initiation thresholds based on the risk categories proposed by 1211 in 2020.				
Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	$\langle OR = 60 \rangle$		
Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60

Phinchkhede.

Dr.Priyal Chinchkhede, MD Consultant Pathologist Dr. Ushma Wartikar, MD Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 12 Of 21

View Details





Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:



8800465156





PATIENT NAME: TRUPTI CHOPADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WI000327 AGE/SEX :35 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : TRUPF010519880

DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 09/09/2023 09:50:15 DELHI ABHA NO REPORTED :11/09/2023 15:17:28 **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL METHOD: COLORIMETRIC DIAZO	0.34	Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.20	< 0.30	mg/dL
BILIRUBIN, INDIRECT	0.14	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: COLORIMETRIC	7.7	6.0 - 8.0	g/dL
ALBUMIN METHOD: COLORIMETRIC	4.5	3.97 - 4.94	g/dL
GLOBULIN	3.2	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.4	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD: UV ABSORBANCE	15	< OR = 35	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV ABSORBANCE	13.5	< OR = 35	U/L
ALKALINE PHOSPHATASE METHOD: COLORIMETRIC	65	35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC	13	0 - 40	U/L
LACTATE DEHYDROGENASE METHOD: UV ABSORBANCE	148	125 - 220	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD: ENZYMATIC ASSAY	8	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD: COLORIMETRIC	0.56	0.5 - 0.9	mg/dL

Bhinchkhede

Dr. Priyal Chinchkhede, MD **Consultant Pathologist**

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head

Page 13 Of 21







Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







Female

PATIENT NAME: TRUPTI CHOPADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

ACCESSION NO : 0181WI000327

PATIENT ID : TRUPF010519880

CLIENT PATIENT ID: ABHA NO : DRAWN ·

AGE/SEX

RECEIVED : 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28

:35 Years

Test Report Status <u>Final</u>	Results	Biological Reference Ir	nterval Units
BUN/CREAT RATIO			
BUN/CREAT RATIO	14.29	8.0 - 15.0	
URIC ACID, SERUM			
URIC ACID METHOD: ENZYMATIC COLORIMETRIC ASSAY	3.4	2.4 - 5.7	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD: COLORIMETRIC	7.7	6.0 - 8.0	g/dL
ALBUMIN, SERUM			
ALBUMIN METHOD: COLORIMETRIC	4.5	3.97 - 4.94	g/dL
GLOBULIN			
GLOBULIN	3.2	2.0 - 3.5	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY	139	136 - 145	mmol/L
POTASSIUM, SERUM METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY	4.45	3.5 - 5.1	mmol/L
CHLORIDE, SERUM METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY	104	98 - 107	mmol/L

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.



Dr.Priyal Chinchkhede, MD Consultant Pathologist Dr. Ushma Wartikar, MD Consultant Pathologist

Shejano

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 14 Of 21





Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:

CIN - U74899PB1995PLC045956

View Details







REF. DOCTOR: SELF PATIENT NAME: TRUPTI CHOPADE

CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WI000327 AGE/SEX :35 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : TRUPF010519880

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHÍ

NEW DELHI 110030 8800465156

CLIENT PATIENT ID: RECEIVED: 09/09/2023 09:50:15 ABHA NO REPORTED: 11/09/2023 15:17:28

DRAWN

Test Report Status Results Biological Reference Interval **Final** Units

Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea), diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, or al contraceptives.

Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.

Increased in: Massive hemolysis. severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole

Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.

Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.

Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction. Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen

in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. **GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billiary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

Bhinchkhede.

Dr. Priyal Chinchkhede, MD Consultant Pathologist

Dr. Ushma Wartikar, MD Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 15 Of 21



Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







Female

REF. DOCTOR: SELF PATIENT NAME: TRUPTI CHOPADE

CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181WI000327

PATIENT ID : TRUPF010519880

CLIENT PATIENT ID: ABHA NO

AGE/SEX :35 Years

DRAWN

RECEIVED: 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28

Test Report Status Results **Biological Reference Interval** <u>Final</u> Units

permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) **Causes of decreased** level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis
TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

@hindrehede

Dr. Priyal Chinchkhede, MD **Consultant Pathologist**

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Dr.(Mrs)Neelu K Bhojani Lab Head

Page 16 Of 21



Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WI000327 AGE/SEX :35 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID :TRUPF010519880

DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 09/09/2023 09:50:15

DELHI ABHA NO REPORTED :11/09/2023 15:17:28 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units **Final**

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW **SLIGHTLY HAZY APPEARANCE**

CHEMICAL EXAMINATION, URINE

PH 6.0 5.00 - 7.50 1.010 - 1.030 SPECIFIC GRAVITY 1.015

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

PROTEIN NOT DETECTED NOT DETECTED **GLUCOSE** NOT DETECTED NOT DETECTED **KETONES** NOT DETECTED NOT DETECTED **DETECTED (TRACE) BLOOD** NOT DETECTED

UROBILINOGEN **NORMAL NORMAL**

NITRITE NOT DETECTED NOT DETECTED LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS 1 - 2 NOT DETECTED /HPF 10-15 /HPF PUS CELL (WBC'S) 0-5 /HPF **EPITHELIAL CELLS** 3-5 0-5

CASTS NOT DETECTED **CRYSTALS** NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED NOT DETECTED YEAST NOT DETECTED

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions	
Proteins	Inflammation or immune illnesses	
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment	

Dr.(Mrs)Neelu K Bhojani Lab Head

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Bhinchkhed

Dr. Priyal Chinchkhede, MD **Consultant Pathologist**



Page 17 Of 21





Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India





DRAWN



PATIENT NAME: TRUPTI CHOPADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WI000327 AGE/SEX :35 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : TRUPF010519880

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED: 09/09/2023 09:50:15 DELHÍ REPORTED :11/09/2023 15:17:28 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr.(Mrs)Neelu K Bhojani Lab Head

Dr. Ushma Wartikar, MD **Consultant Pathologist**

Bhinchkhede

Dr.Priyal Chinchkhede, MD **Consultant Pathologist**





Page 18 Of 21



Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:





REF. DOCTOR: SELF



PATIENT NAME: TRUPTI CHOPADE

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0181WI000327

PATIENT ID : TRUPF010519880

CLIENT PATIENT ID: ABHA NO : AGE/SEX : 35 Yea

:35 Years Female

DRAWN :

RECEIVED : 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION,STOOL
COLOUR

METHOD : VISUAL

SAMPLE NOT RECEIVED

Ssourant

Dr. Sheetal Sawant, MD Consultant Microbiologist





Page 19 Of 21

View Details

Niew Depart

PERFORMED AT:

Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax:







Female

PATIENT NAME: TRUPTI CHOPADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : **0181WI000327**

PATIENT ID : TRUPF010519880

CLIENT PATIENT ID: ABHA NO : AGE/SEX :35 Years

AWN :

RECEIVED : 09/09/2023 09:50:15 REPORTED :11/09/2023 15:17:28

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

T3 111.0 Non-Pregnant Women ng/dL

80.0 - 200.0 Pregnant Women

1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0

METHOD: ELECTROCHEMILUMINESCENCE

T4 7.14 Non-Pregnant Women μg/dL

5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70

METHOD: ELECTROCHEMILUMINESCENCE

TSH (ULTRASENSITIVE) 1.710 Non Pregnant Women µIU/mL

0.27 - 4.20 Pregnant Women

1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15

METHOD: ELECTROCHEMILUMINESCENCE

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No. TSH Total T4 FT4 Total T3 Possible Conditions

Dr.(Mrs)Neelu K Bhojani Lah Head Bhinchkhede.

Dr.Priyal Chinchkhede, MD Consultant Pathologist Dr. Ushma Wartikar, MD Consultant Pathologist

Page 20 Of 21





View Details

View Repor

Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India







CODE/NAME & ADDRESS : C000138394 ACCESSION NO : **0181WI000327** AGE/SEX : 35 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : TRUPF010519880 DRAWN :

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 09/09/2023 09:50:15

NEW DELHI 110030 ABHA NO : REPORTED :11/09/2023 15:17:28 8800465156

Test Report Status <u>Final</u> Results Biological Reference Interval Units

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr.(Mrs)Neelu K Bhojani Lab Head

Dr.Priyal Chinchkhede, MD Consultant Pathologist

Phinchehede

Dr. Ushma Wartikar, MD Consultant Pathologist Page 21 Of 21











Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India

